Recent Updates
Recently added Catalysts
ALT Negative Sentiment Score: 25/100

Altimmune, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – ALT

Key Takeaway: Altimmune, Inc. is facing a class action securities lawsuit filed by Levi & Korsinsky, LLP, which claims that the company misled investors regarding the potential and trial results of its lead product candidate, pemvidutide. The lawsuit pertains to alleged securities fraud occurring between December 1, 2023, and April 26, 2024. Investors who suffered losses during this period are encouraged to take action by contacting the firm. The case emphasizes potential discrepancies in the company's public statements about its drug's efficacy and commercial viability.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Altimmune for alleged securities fraud.
  • Allegations include overstating the potential of its drug candidate pemvidutide.
  • Claims that clinical trial results were misrepresented to investors.

Full Press Release Details

NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between December 1, 2023 and April 26, 2024. Follow the link below to get more information and be contacted by a member of our team:
ALT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Altimmune overstated the potential for its lead product candidate, pemvidutide, to stand out from competing glucagon-like peptide-1 agonists based on the drug’s efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial results were less significant to pemvidutide’s clinical, commercial, and competitive prospects than Defendants had led investors to believe; (iii) as a result of all the foregoing, defendants had overstated Altimmune’s prospects for finding a strategic partner to develop pemvidutide; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Altimmune during the relevant time frame, you have until July 5, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the Altimmune class action lawsuit about?

The lawsuit addresses alleged securities fraud impacting Altimmune investors from December 2023 to April 2024.

Who can join the Altimmune class action lawsuit?

Investors who suffered losses in Altimmune during the relevant period can join.

Is there a cost to join the Altimmune lawsuit?

There are no costs or fees for class members wishing to participate.

What is the deadline to become a lead plaintiff?

The deadline to request lead plaintiff status is July 5, 2024.

How can I contact Levi & Korsinsky for more information?

You can email Joseph E. Levi at jlevi@levikorsinsky.com or call (212) 363-7500.

Last updated: May 21, 2024